Compare EVI & RNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EVI | RNA |
|---|---|---|
| Founded | 1959 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 204.6M | 222.5M |
| IPO Year | 1995 | 2025 |
| Metric | EVI | RNA |
|---|---|---|
| Price | $17.89 | $9.16 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 20 |
| Target Price | $35.00 | ★ $69.26 |
| AVG Volume (30 Days) | 43.4K | ★ 336.2K |
| Earning Date | 05-15-2026 | 01-01-0001 |
| Dividend Yield | ★ 1.81% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.48 | N/A |
| Revenue | ★ $389,830,000.00 | N/A |
| Revenue This Year | $15.53 | $88.12 |
| Revenue Next Year | $3.83 | $18.11 |
| P/E Ratio | $36.82 | ★ N/A |
| Revenue Growth | ★ 10.26 | N/A |
| 52 Week Low | $12.75 | $8.66 |
| 52 Week High | $34.75 | $73.06 |
| Indicator | EVI | RNA |
|---|---|---|
| Relative Strength Index (RSI) | 71.62 | 29.37 |
| Support Level | $16.41 | N/A |
| Resistance Level | $21.36 | $14.39 |
| Average True Range (ATR) | 1.09 | 0.77 |
| MACD | 0.41 | -0.40 |
| Stochastic Oscillator | 93.57 | 9.27 |
EVI Industries Inc is a value-added distributor and service provider in the commercial laundry industry. It sells and leases commercial laundry equipment, specializing in washing, drying, finishing, material handling, water heating, power generation, and water reuse applications. The company supports its equipment offerings with installation, maintenance, and repair services through a large network of trained technicians. It serves a wide range of customers, including commercial, industrial, institutional, government, and retail sectors. Geographically, the company serves various countries including United States, Canada, the Caribbean, and Latin America.
Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.